SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LLCF who wrote (84)1/25/1999 9:04:00 AM
From: Biomaven  Read Replies (1) of 3158
 
David,

MRK's pretty much dependent on Vioxx now, and its pipeline is much thinner than it needs to compensate for its patent expirations.

Here's a (not great) link describing its pipeline, from MRK's 1997 annual report:

merck.com!!vzb4g1yflvzbL61CcT/overview/97ar/p10.htm

Here's a great link detailing forthcoming patent expirations at the big pharmas:

labpuppy.com

Further depressing the sector, read today's NY Times article on HMO and insurance company efforts to reduce reimbursements on many drugs.

MRK would have to gobble an awful lot of biotechs to make any appreciable dent in its pipeline deficit. SEPR would do it, but please don't tell MRK <G>.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News